Abiopharma

New Form 8-K - INDIVIOR PLC Filed: 2025-08-26 AccNo: 0001625297-25-000059 Size: 143 KB Item 2.05: Cost Associated with Exit or Disposal Activities

New Form 6-K - GSK plc Filed: 2025-08-26 AccNo: 0001654954-25-009996 Size: 5 MB

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

New Form 8-K - Venus Concept Inc. Filed: 2025-08-26 AccNo: 0001140361-25-032608 Size: 164 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Cybin - Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Altimmune to Participate in Upcoming Investor Conferences

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

New Form 6-K - Haleon plc Filed: 2025-08-26 AccNo: 0001654954-25-009994 Size: 40 KB

New Form 8-K - Marker Therapeutics, Inc. Filed: 2025-08-26 AccNo: 0001104659-25-082783 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits